
Nova Mentis (OTC: NMLSF) Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial
Vancouver, British Columbia– April 11, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for […]